U.S. attorneys general urge the FDA to combat counterfeit versions of weight loss drugs developed by Eli Lilly (LLY) and Novo Nordisk (NVO). Read more here.
Compounders sue FDA again over declaring end of shortage for Novo's semaglutide
US FDA says shortage of Novo's weight-loss drug resolved
The resolution comes two months after the health regulator said there was no longer a shortage of Eli Lilly's weight-loss and diabetes drugs. All doses of Novo's diabetes treatment Ozempic and weight-loss drug Wegovy were listed as available on the FDA's website in October,
FDA declares end to Ozempic and Wegovy shortage
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday. The update about the popular semaglutide injections from drug manufacturer Novo Nordisk follows just two months after the FDA said that shortages of tirzepatide injections Zepbound and Mounjaro from competitor Eli Lilly had also ended.
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply squeeze on Novo Nordisk’s diabetes and obesity counterpa | The FDA has officially declared an end to the supply squeeze on Novo Nordisk’s GLP-1 drug semaglutide for diabetes and obesity in the U.
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the end to the booming market for cheaper versions made by pharmacies.
(Reuters) - Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at a $150 discount to the cost of the injector pen versions, as it seeks to spur further demand for the medicine.
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.
4don MSN
Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug is no longer on the FDA shortage list.
The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.
Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S. Food and Drug Administration
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback